Literature DB >> 3978318

The effects of meptazinol in comparison with pentazocine, morphine and naloxone in a rat model of anaphylactic shock.

P M Paciorek, M H Todd, J F Waterfall.   

Abstract

The actions of meptazinol, pentazocine, morphine and naloxone on the cardiovascular changes accompanying anaphylactic shock were evaluated in ovalbumin-sensitized anaesthetized rats. Pretreatment with meptazinol and pentazocine prevented the fall in mean arterial pressure associated with antigen challenge, whereas morphine and naloxone attenuated but did not completely prevent, this change. None of the drugs significantly altered the antigen-induced decreases in heart rate. All the drugs partially reversed the fall in mean arterial pressure when given after antigen challenge although the activity of naloxone was less marked. Pretreatment with reserpine prevented the restoration of blood pressure by all drugs. Additional experiments with meptazinol showed that pretreatment with phentolamine prevented its pressor action. In pithed non-sensitized rats the frequency-pressor response curve to splanchnic stimulation was shifted to the left by meptazinol and shifted to the right by pentazocine, but the changes were small Morphine and naloxone had no significant effects. It was concluded that opioid mixed agonist-antagonists reverse the cardiovascular changes associated with anaphylactic shock. These effects appear to be mediated by facilitation of sympathetic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978318      PMCID: PMC1987277          DOI: 10.1111/j.1476-5381.1985.tb12931.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  THE EFFECT OF MORPHINE, MEPERIDINE, AND THIOPENTAL IN HYPOVOLEMIC SHOCK.

Authors:  E A CHASNOW; H S SMALL; J H HENRY; E M PAPPER; G G NAHAS
Journal:  Surgery       Date:  1964-04       Impact factor: 3.982

2.  Anaphylactic shock in the albino rat.

Authors:  R K SANYAL; G B WEST
Journal:  J Physiol       Date:  1958-08-06       Impact factor: 5.182

3.  Blockade of opiate receptors with naloxone improves survival and cardiac performance in canine endotoxic shock.

Authors:  D G Reynolds; N J Gurll; T Vargish; R B Lechner; A I Faden; J W Holaday
Journal:  Circ Shock       Date:  1980

4.  A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat.

Authors:  J S Gillespie; T C Muir
Journal:  Br J Pharmacol Chemother       Date:  1967-05

5.  Effect of pentazocine and pethidine on plasma catecholamine levels.

Authors:  T Tammisto; A Jäättelä; P Nikki; S Takki
Journal:  Ann Clin Res       Date:  1971-02

6.  Opiate antagonists improve survival in anaphylactic shock.

Authors:  S Amir
Journal:  Eur J Pharmacol       Date:  1982-05-07       Impact factor: 4.432

7.  Dopamine partially mediates the cardiovascular effects of naloxone after spinal injury.

Authors:  A I Faden; T P Jacobs; G Feuerstein; J W Holaday
Journal:  Brain Res       Date:  1981-06-01       Impact factor: 3.252

8.  Pressor effect of naloxone in septic shock.

Authors:  W P Peters; M W Johnson; P A Friedman; W E Mitch
Journal:  Lancet       Date:  1981-03-07       Impact factor: 79.321

9.  The action of porcine glucagon on the motility of the canine duodenum and jejunum.

Authors:  D F Evans; G E Foster; J D Hardcastle; F Jonhson; J W Wright
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

10.  Restoration of mean arterial pressure in endotoxic shock by meptazinol. Contributions from lysosomal membrane stabilisation, opiate antagonism and noradrenaline release.

Authors:  P M Paciorek; M H Todd; M G Wyllie
Journal:  Biochem Pharmacol       Date:  1983-03-01       Impact factor: 5.858

View more
  1 in total

1.  Comparison of the cardiovascular effects of meptazinol and naloxone following haemorrhagic shock in rats and cats.

Authors:  E Chance; P M Paciorek; M H Todd; J F Waterfall
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.